5th CML-CAB: Warsaw, Poland, 7-8 May 2018
On 7-8 May 2018, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, hosted its 5th meeting to discuss issues of major concern to the CML community. The meeting was made up of 3 sessions: Novartis, Pfizer, Incyte.
The following topics were discussed during the session with Novartis, 7th May 2018, 13:00-17:00:
- ABL001 – Clinical Development Program Updates
- Patient-Reported Outcomes
- Precision Medicine –Novartis strategy in CML
- TFR/CML educational materials
- Novartis access program
- Discussion and Next Steps
The following topics were discussed during the session with CML-CAB with Pfizer, 8th May 2018, 08:00-12:00:
- Clinical and Medical Update
- Use of Patient report outcomes and in Bosutinib’s clinical trial program
- Patient and physician information on Bosutinib
- Access to Bosutinib
- Collaboration with Pfizer and challenges
- Discussion and Next Steps
The following topics were discussed during the session with CML-CAB with Incyte 8th May 2018, 13:00-15:00:
- Clinical update and R&D
- Access to Ponatinib
- The collaboration of Incyte with the CML patient community
- Incyte’s CML Patient Support Program
- Discussion and Next Steps